Treating Chronic Pelvic Pain in 2026: New Paradigms

Treatment of chronic pelvic pain in 2026 is moving away from diagnosis-siloed care and toward phenotype-based, multimodal management. That shift reflects the reality that many patients with different diagnostic labels share the same underlying pelvic floor dysfunction and regional pain sensitization.

1. Limits of Traditional Treatment

Traditional treatments still have a role, but many patients do not achieve durable relief with medications or surgery alone. This is especially true when chronic pain has become amplified by myofascial dysfunction, central sensitization, and overlapping bladder, bowel, vulvar, or neuropathic symptoms.

Surgery may help selected patients, particularly when there is clearly defined pathology such as endometriosis. However, outcomes are often less predictable when the pelvic floor remains hypertonic and tender or when more than one pain mechanism is active.

2. Pelvic Floor Therapy as Core Care

Pelvic floor physical therapy remains one of the most important components of care for patients with documented tenderness and high-tone dysfunction. Randomized trial data support myofascial physical therapy in women with IC/BPS and pelvic floor tenderness, reinforcing the importance of treating the muscular component of pain.

At the same time, real-world adherence can be a challenge. That gap between efficacy and completion has led to growing interest in office-based adjuncts that can target similar mechanisms in patients who struggle with prolonged therapy pathways.

3. The Rise of Non-Ablative Photobiomodulation

One of the notable developments in 2026 is the growing attention to non-ablative photobiomodulation. Unlike ablative vaginal lasers, which depend on tissue injury and wound healing, photobiomodulation aims to influence tissue metabolism, circulation, and pain signaling without thermal destruction.

The proposed mechanisms include modulation of mitochondrial activity, nitric oxide signaling, microcirculation, and nociceptive pathways in affected tissues. This makes PBM conceptually attractive for chronic pelvic pain because many patients exhibit muscle overactivity, local tissue stress, and persistent pain signaling regardless of their specific diagnosis.

4. Why SoLá May Work Across Diagnoses

SoLá Pelvic Therapy is best understood as a phenotype-based intervention rather than a diagnosis-specific intervention. In real-world practice, it appears to show benefit across a range of CPP-associated diagnoses because many of those diagnoses share the same clinically important finding: a hypertonic, tender pelvic floor.

That includes patients labeled with IC/BPS, endometriosis-associated pelvic pain, IBS-associated pelvic pain, vulvodynia, and pudendal neuralgia when pelvic floor dysfunction is part of the clinical picture. In this setting, the treatment target is the shared myofascial and metabolic dysfunction rather than the initiating diagnosis alone.

5. Real-World Evidence for TV-PBM

In a preliminary observational study of women with pelvic muscle tenderness and IC/BPS, transvaginal photobiomodulation was associated with clinically meaningful improvement in pelvic pain symptoms. Specifically, 63.9% of participants achieved a reduction of at least 2 points on the numeric rating scale after treatment, with improvement seen in overall pain as well as pain with urination, exercise, and intercourse.

These findings support the broader concept that therapies directed at pelvic floor tenderness and related tissue dysfunction may help across diagnostic categories. In other words, SoLá may appear similarly effective across different CPP-associated diagnoses because the underlying pelvic floor phenotype is often the same.

6. The 2026 Treatment Model

The emerging treatment model for chronic pelvic pain is multimodal, but not random. The most effective plans start by identifying the dominant pain mechanisms and then layering therapies appropriately, with pelvic floor dysfunction management often serving as the foundation.

For patients with high-tone pelvic floor dysfunction, this may include pelvic floor physical therapy, behavioral strategies, pain modulation, bladder or bowel-directed treatment when needed, and office-based options such as transvaginal photobiomodulation. This is the practical meaning of a phenotype-based treatment strategy in 2026.

Bibliography

As-Sanie S, Ross WT, Till SR. Evaluation and Treatment of Chronic Pelvic Pain. Obstet Gynecol. 2026;147(1):21-43.

Butrick CW, Lamvu G. Transvaginal Photobiomodulation Improves Pain in Women with Pelvic Muscle Tenderness and Interstitial Cystitis/Bladder Pain Syndrome: A Preliminary Observational Study. Urology. 2022;170:14-20.

Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516-533.

FitzGerald MP, Payne CK, Lukacz ES, et al. Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. J Urol. 2012;187(6):2113-2118.

Gupta P, Chen J, Kutch JJ, et al. Is Pelvic Floor Muscle Tenderness a Distinct Urologic Chronic Pelvic Pain Syndrome Phenotype? J Urol. 2022;208(2):341-349.

Kohli N, Jarnagin B, Stoehr AR, Lamvu G. An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain. J Comp Eff Res. 2021;10(17):1291-1299.

Lamvu G, Carrillo J, Ouyang C, Rapkin A. Chronic pelvic pain in women: a review. JAMA. 2021;325:2381-2391.

Leonardi M, et al. Surgical interventions for the management of chronic pelvic pain in women. Cochrane Database Syst Rev. 2021;12:CD008212.

Woodburn KL, et al. Compliance with pelvic floor physical therapy in patients diagnosed with high-tone pelvic floor disorders. Female Pelvic Med Reconstr Surg. 2019.

Zipper R, Pryor B, Lamvu G. Transvaginal Photobiomodulation for the Treatment of Chronic Pelvic Pain: A Pilot Study. Womens Health Rep (New Rochelle). 2021;2(1):518-527.